

A machine-learning method for biobank-scale genetic prediction of blood group antigens

Hyvärinen K^{1*}, Haimila K², Moslemi C^{3,4}, Blood Service Biobank⁵, Olsson ML^{6,7}, Ostrowski SR^{8,9}, Pedersen OB^{3,9}, Erikstrup C¹⁰, Partanen J¹, Ritari J¹

1. *Research and Development, Finnish Red Cross Blood Service, Helsinki, Finland*
2. *Blood Group Unit, Finnish Red Cross Blood Service, Vantaa, Finland*
3. *Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark*
4. *Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark*
5. *Finnish Red Cross Blood Service, Vantaa, Finland*
6. *Department of Laboratory Medicine, Lund University, Lund, Sweden*
7. *Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Region Skåne, Sweden*
8. *Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark*
9. *Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark*
10. *Department of Clinical Immunology, Aarhus University Hospital, Skejby, Denmark*

Short title: Blood group prediction method

*Corresponding author:

Kati Hyvärinen, PhD, Associate professor

Finnish Red Cross Blood Service

Research and Development

Biomedicum Helsinki 1, Haartmaninkatu 8, 00290 Helsinki, FINLAND

Phone +358 40 920 3083

kati.hyvarinen@bloodservice.fi

1 ABSTRACT

2 Blood transfusion is a life-saving medical procedure performed routinely worldwide. A key
3 element for successful transfusion is compatibility of the patient and donor red blood cell
4 (RBC) antigens. Precise antigen matching reduces the risk for immunization and other
5 adverse transfusion outcomes. RBC antigens are encoded by specific genes, which allows
6 developing computational methods for determining antigens from genomic data.

7 We describe here a classification method for determining RBC antigens from genotyping
8 array data. Random forest models for 39 RBC antigens in 14 blood group systems and for
9 human platelet antigen (HPA)-1 were trained and tested using genotype and RBC antigen
10 and HPA-1 typing data available for 1,192 blood donors in the Finnish Blood Service
11 Biobank. The algorithm and models were further evaluated using a validation cohort of
12 111,667 Danish blood donors.

13 In the Finnish test data set, the median (interquartile range [IQR]) balanced accuracy for 39
14 models was 99.9 (98.9–100)%. We were able to replicate 34 out of 39 Finnish models in the
15 Danish cohort and the median (IQR) balanced accuracy for classifications was 97.1 (90.1–
16 99.4)%. When applying models trained with the Danish cohort, the median (IQR) balanced
17 accuracy for the 40 Danish models in the Danish test data set was 99.3 (95.1–99.8)%.

18 The RBC antigen and HPA-1 prediction models demonstrated high overall accuracies
19 suitable for probabilistic determination of blood groups and HPA-1 at biobank-scale.
20 Furthermore, population-specific training cohort increased the accuracies of the models.
21 This stand-alone and freely available method is applicable for research and screening for
22 antigen-negative blood donors.

23

24

25

26 Keywords

27 Red blood cell antigen, blood group, random forest, classification, biobank, blood donor

28 INTRODUCTION

29 Blood transfusion is a life-saving procedure performed widely in treating various medical
30 conditions. Despite routine practices, the safety of transfusions remains a major concern¹.
31 Exposure to foreign RBC antigens may result in alloantibody formation and hemolytic
32 transfusion reactions. Additionally, sensitization to non-self RBC antigens and human
33 platelet antigens (HPAs) can also occur via pregnancy and cause fetal morbidity and
34 mortality^{2,3}. The current general practice of matching the recipient and blood donor for ABO
35 and RhD antigens is inadequate to prevent sensitization to other antigens. Extended
36 matching could reduce the risk of alloimmunization and adverse events, which are especially
37 pronounced among patients receiving regular transfusions^{4,5}.

38 Blood group typing of blood donors has been conventionally performed by serotyping and is
39 still the main method used in blood centers. To overcome limitations regarding low
40 throughput and lack of valid reagents for all clinically relevant antigens, numerous DNA-
41 based genotyping and sequencing methods have emerged within the last decades^{6–10}. This
42 development has been enabled by the accumulating knowledge about the genetic basis of
43 the blood groups^{11,12} and the rapid evolution of molecular methodology. However, the
44 systematically extended blood group typing of blood donors and, even more so, the
45 recipients, remains sparse. Economic feasibility has been a major restraint to the progress.
46 The development of genotyping array technologies has promoted high-throughput and cost-
47 effective genetic studies in many fields and, in 2020, Gleadall *et al.*¹³ introduced a
48 microarray platform for RBC antigen, human leukocyte antigens (HLA), and HPA typing for
49 precision matching of blood.

50 While accurate blood group typing is obligatory for safe transfusions, an initial screening for
51 potential donors could be achieved using less stringent procedures. In the last decade, the
52 development of machine learning approaches for high-dimensional data has provided new
53 opportunities for exploitation of expanding genetic data. In 2015, Giollo *et al.*¹⁴ presented
54 BOOGIE, an RBC antigen predictor based on Boolean rules and *k*-nearest neighbor (*k*-NN)
55 algorithm. Decision tree -based methods, including bootstrap aggregation¹⁵ and random
56 forest¹⁶, have been utilized for imputation of HLA alleles^{17,18} and killer cell immunoglobulin-
57 like receptor (KIR) copy number¹⁹ and gene content²⁰. To our knowledge, these methods

58 have not yet been implemented on RBC antigen and HPA screening. The analysis of high-
59 dimensional data with computational performance suitable for large-scale analyses may be
60 implemented using “RANDOM forest GEnERator” software R package²¹. The execution is
61 feasible in the local computing environment and sensitive data uploads are not required.

62 Here we describe a stand-alone and freely available random forest classification method
63 and models for determining RBC antigens and HPA-1 from array technology-based
64 genotyping data. We investigate the performance of models trained with Finnish blood
65 donor biobank data and further validate the method with a Danish cohort. Our results
66 suggest that the method is applicable for biobank-scale probabilistic determination of RBC
67 antigens and HPA-1, and could facilitate research and screening for antigen-negative blood
68 donors.

69

70 **STUDY SUBJECTS AND METHODS**

71 *Study cohorts and design*

72 The Finnish study cohort consists of 1,192 blood donors belonging to the Blood Service
73 Biobank, Helsinki, Finland (<https://www.veripalvelu.fi/en/biobank/>). Genotype and blood
74 group phenotype data were obtained from the Blood Service Biobank. The study (biobank
75 decision 002-2018) conforms to the principles of the Finnish Biobank Act (688/2012) and the
76 participants have given written informed consent to the Blood Service Biobank.

77 The Danish validation cohort consists of 111,667 participants of the Danish Blood Donor
78 Study (DBDS) Genomic Cohort expanding on the Danish blood bank system^{22,23}. The genetic
79 studies in DBDS have been approved by the Danish Data Protection Agency (P-2019-99) and
80 the Scientific Ethical Committee system (NVK-1700407).

81

82 *Genotyping and genotype imputation*

83 The genotyping and genotype imputation of the Finnish cohort have been performed
84 originally as a part of FinnGen project (<https://www.finnngen.fi/en>). Biobank samples were
85 genotyped using FinnGen ThermoFisher Axiom custom array v2 (Thermo Fisher Scientific,

86 Santa Clara, CA, USA) and imputed using the population-specific Sisu v3 imputation
87 reference panel with Beagle 4.1. Detailed description of the procedures is available at
88 <https://finngen.gitbook.io/documentation/v/r4/methods/genotype-imputation> and the
89 marker content of the custom array v2 is downloadable at
90 <https://www.finngen.fi/en/researchers/genotyping>. The phased genotypes were filtered for
91 the imputation INFO-score >0.6 and were in vcf format.

92 In the Danish cohort, the genotyping was performed using Illumina's Infinium Global
93 Screening Array and imputed using the deCODE genetics' (Reykjavik, Iceland) North
94 European reference sequence panel. Unphased genotypes were filtered for the imputation
95 INFO-score >0.75, minor allele frequency >0.01, Hardy–Weinberg equilibrium P-values <1
96 $\times 10^{-4}$, and samples for missingness per individual <3%.

97

98 *RBC antigen and HPA typing*

99 The RBC antigen and HPA-1 phenotypic information for the Finnish and Danish cohorts is
100 presented in **Table 1**. The availability of the phenotype data varied in a wide range
101 depending on the antigen due to the different testing criteria practices. In the Finnish
102 cohort, RBC antigen and HPA-1 typing was performed at the FRCBS Blood Group Unit by
103 routine methods and the results were obtained using validated serological and genotyping
104 techniques.

105 The sources for RBC antigen and HPA-1 typing results were the Danish electronic blood bank
106 systems and the typing was performed using serological methods, except for Vel-status,
107 which was determined using polymerase chain reaction technique.

108

109 *Classification random forest models*

110 An overview of the study design is depicted in **Figure 1**. RBC antigen and HPA-1 coding genes
111 and the genetic regions used in the models are presented in **Supplementary Table 1**. The
112 models for the antigens were generated separately using the same hyperparameters. Only
113 antigens having at least four cases in each respective typing data class were included,
114 resulting altogether in 39 models. For the Finnish reference data set, SNVs in RBC antigen

115 and HPA-1 coding genetic regions \pm 2,000 bp flanking regions were utilized in dosage
116 format. **Table 2** presents the number of SNVs available for each model. Only samples having
117 full dosage data were used. The genetic and antigen typing information were combined into
118 a single full data set and divided randomly 1:1 into train and test data sets.

119 R v4.3.0 environment²⁴ was used for the implementation and classification random forest
120 models were created using the R package ranger v0.13.1²¹. The number of trees was 2,000
121 and split criteria based on node impurity measured by the Gini index. Class weights were
122 applied due to unbalanced outcome classes. Number of variables to possibly split at each
123 node (mtry) was number of SNVs divided by 2 and the variable importance was determined
124 by permutation. Feature selection was based on variable importance >0 and the model was
125 re-fitted using these important SNVs only. The number of important variables and
126 prediction errors for each antigen model are presented in the **Table 2**. Prediction error was
127 determined as misclassification frequency obtained from out-of-bag data and prediction on
128 the test set. The important variables for Finnish models are listed in **Supplementary Data 2**.
129 The full data set was used in fitting the final models.

130

131 *Model evaluation metrics*

132 The model accuracy was evaluated using sensitivity, specificity, positive predictive value
133 (PPV), negative predictive value (NPV), and balanced accuracy. The data was wrangled using
134 tidyverse v1.3.1 package²⁵ and the evaluation metrics were derived using caret v6.0-92²⁶.
135 For each model, the number of true positives (TP), true negatives (TN), false positives (FP)
136 and false negatives (FN) were determined. Sensitivity was defined as $TP / (TP + FN)$,
137 specificity as $TN / (TN + FP)$, PPV as $TP / (TP + FP)$, NPV as $TN / (TN + FN)$ ²⁷. Balanced
138 accuracy accounts for imbalanced classification and was defined as $(\text{sensitivity} + \text{specificity})$
139 $/ 2$.

140

141 *Validation of the Finnish models and the random forest method for generating the models*

142 The models obtained using the Finnish data set were applied to the Danish cohort. The
143 implementation required imputed genotype data in vcf or PLINK format. The Danish allele

144 dosage data was harmonized by naming and allele orientation for compatibility with the
145 Finnish models and the dosage data for the missing important variables was imputed using
146 mean values.

147 The model-generating method was further validated by fitting the models on the Danish
148 data set to create models specific to the Danish cohort. In the Danish data set, the
149 percentage of missing genotypes was on average 5% depending on the genetic region of the
150 blood group/HPA system. Missing allele dosage values were imputed separately for train
151 and test data sets using mean values before classification random forest step.

152 Characteristics of the Danish models are presented in **Supplementary Table 2**. The
153 important variables for the Danish models are listed in **Supplementary Data 3**. The
154 evaluation metrics for both prediction and modelling were defined as depicted in the
155 “*Model evaluation metrics*” section.

156 The significance of variation of balanced accuracies was analyzed using Mann-Whitney-
157 Wilcoxon Test implemented with R v3.6.1.

158

159 *Data availability*

160 Genotyping and RBC antigen/phenotype and HPA-1 typing data for the Finnish cohort are
161 stored in the Blood Service Biobank, Helsinki, Finland. Researchers may apply for access to
162 data (<https://www.veripalvelu.fi/en/biobank/for-researchers/>). Due to privacy laws, the
163 Danish genetic data and phenotypes are only available to DBDS researchers and blood
164 banks.

165

166 RESULTS

167 *Evaluation of the Finnish classification models*

168 In the Finnish cohort, the genotype data was accessible for 1,192 blood donors and the RBC
169 antigen typing data was available for 39 antigens representing 15 blood group systems. The
170 blood group typing frequency varied greatly depending on RBC antigen/phenotype, being at
171 the lowest 5% for HPA-1b and at the highest 100% for A, B, AB, O, K, D, C, c, E, and e (**Table**
172 **1**).

173 After data partitioning, the number of study subjects in the test data set was 596. The
174 median (interquartile range [IQR]) balanced accuracy for 39 models was 99.9 (98.9–100)% in
175 the test data set and accuracy metrics for all models are presented in the **Table 3**. The
176 models for antigen/phenotype positivity of AB, B, A₁, A₂, Yt^b, Co^a, Do^a, Do^b, Fy^a, HPA-1b, K,
177 Kp^a, Ul^a, Jk^a, Lu^a, S, and s reached balanced accuracy of 100%. For other models, the
178 balanced accuracy was ≥98.0%, except 83.3% for Ls^a, 94.0% for Le^b, 95.0% for HPA-1a, and
179 96.0% for hr^S. Accuracy metrics for the test and full data sets are presented in the
180 **Supplementary Tables 3 and 4**, respectively. **Figure 2** illustrates the confusion matrices for
181 classification models in the Finnish test data set. The number of false negative plus false
182 positive (FN + FP) samples out of all samples was low, ranging from 0 to 1% in all models,
183 except 2% for hr^S. Confusion matrices for the test and full data sets are presented in
184 **Supplementary Figures 1 and 2**, respectively. The median (IQR) prediction error,
185 determined as misclassification frequency obtained from out-of-bag data, of the Finnish
186 models was 1.6×10^{-3} (1.9×10^{-4} – 7.0×10^{-3}) (**Table 2**).

187 The distributions of posterior probabilities (PP) in the test data set are depicted in **Figure 3**.
188 The samples having PP >0.5 were classified as antigen positive and ≤0.5 as antigen negative.
189 The majority of the PPs were close to 1 for the antigen typing positive samples and close to
190 0 for the antigen typing negative samples. The Co^a-negative samples (only two samples in
191 the test data set) were classified correctly but the PPs were closer to 0.5 than to 0. One of
192 the three Ls^a-positive samples were misclassified and the PPs for the other two were closer
193 to 0.5 than to 1 (specificity 66.7%). The spectrum of PP distribution with some
194 misclassifications was observed for Co^b, Le^b, M, N, C, C^w, D, and hr^S. **Supplementary Figures**
195 **3 and 4** depict the distributions of PPs in the test and full data sets.

196

197 *Validation of the Finnish classification models in the Danish cohort*

198 The Danish validation cohort had genotype and phenotype data for 34 out of the 39 Finnish
199 classification models. Antigen/phenotype typing data varied from 433 for A₂ to ~111,000 for
200 A, AB, B, O, and D (**Table 1**). Due to missing Finnish model variables in the Danish genotype
201 data, the Danish allele dosage data was harmonized using mean imputation before applying
202 the Finnish models.

203 The median (IQR) balanced accuracy for classifications was 97.1 (90.1–99.4)% and all the
204 evaluation metrics are presented in **Supplementary Table 4**. The balanced accuracies were
205 >98.0% for 14 models including antigen/phenotype positivity of A, AB, B, O, Yt^b, Do^a, Do^b,
206 HPA-1a, Jk^a, Le^a, S, s, E, and e. Models for antigen/phenotype positivity of A₁, Co^b, Fy^a, Fy^b,
207 HPA-1b, K, Kp^a, Lu^a, M, N, and C^w had balanced accuracy ranging from 91.6 to 98.0%. Six
208 models, A₂, Co^a, Jk^b, Le^b, D, and C had balanced accuracy ranging from 64.6 to 89.4%. The
209 Finnish models for LW^b, P1, and c failed classification in the Danish cohort.

210

211 *Validation of the classification model algorithm in the Danish cohort*

212 The RBC antigen/phenotype and HPA-1 typing and genotype data available for the Danish
213 cohort enabled implementation of 40 Danish classification models representing 15 blood
214 group systems. Due to missing genotypes (approximately 5%), missing allele dosage values
215 were imputed separately for train and test data sets using mean values.

216 Median (IQR) balanced accuracy for the 40 Danish models in the Danish test data set was
217 99.3 (95.1–99.8)%. The evaluation metrics for test data set are available in **Table 4** and for
218 the train and full data sets in **Supplementary Tables 6–7**, respectively. Majority (23/40) of
219 the Danish models reached balanced accuracy of ≥99.0% including models for
220 antigen/phenotype positivity of A, AB, B, O, Yt^a, Yt^b, Do^a, Do^b, Fy^a, HPA-1a, HPA-1b, Jk^a, Jk^b,
221 M, N, S, s, C, c, D, E, Le^a, and Kn^b. Balanced accuracies for A₁, Co^b, Fy^b, K, Kp^a, Lu^a, C^w, e, and
222 P1 models ranged from 94.4 to 98.1%, and for A₂, Co^a, k, Kp^b, Lu^b, Vel, and Le^b from 70.0 to
223 89.3%. Danish model for Kn^a failed classification due to too low number of Kn^a-negative
224 samples in the test data set. Confusion matrices for the Danish models in the Danish train,

225 test and full data sets depict the distribution of TN, FN, TP, and FP samples and are
226 illustrated in **Supplementary Figures 5–7**, respectively. The median (IQR) prediction error of
227 the Danish models was 2.3×10^{-3} ($9.3 \times 10^{-4} - 7.1 \times 10^{-3}$)% (**Supplementary Table 5**).

228

229 *Comparison of the Finnish and Danish classification models*

230 Assembly of the balanced accuracies for Finnish and Danish models in the Finnish and
231 Danish full data sets is presented in **Table 5**. When analyzing the shared 33 models, the
232 Finnish models predicted the blood groups of the Finnish cohort more accurately than the
233 blood groups of the Danish cohort (median [IQR] balanced accuracy 99.9 [98.8–100]% vs.
234 97.1 [91.6–99.5], $p = 1.15e-06$). The Danish models were performing better than the Finnish
235 models in the blood group classification of the Danish cohort (median [IQR] balanced
236 accuracy 99.5 [96.5–99.8]% vs. 97.1 [91.6–99.5]%, $p = 0.006$).

237 The number of genetic variants available for the Finnish random forest modelling ranged
238 from 35 to 688 depending on the blood group/HPA system and number of the important
239 variables selected by the classifier for the final models ranged from 12 to 214 (**Table 2**). In
240 the Danish genotyping data set, the number of variants varied from 42 to 766 and the final
241 models utilized 20–743 variants (**Supplementary Table 5**).

242

243

244

245 DISCUSSION

246 Our study introduces random forest classification models for predicting RBC
247 antigens/phenotypes and HPA-1 from array-based genotyping data. The method and
248 models were generated utilizing blood group typing data from Finnish blood donors and
249 further validated using a large Danish blood donor cohort. The results demonstrate high
250 overall accuracy, and the method is suitable for biobank-scale screening and analysis of
251 HPA-1 and RBC antigens.

252 Blood transfusion is one of the most common clinical procedures in the hospitals and the
253 key element for safe transfusion is compatibility between the recipient and donor RBC
254 antigens¹. Although transfusion-related severe outcomes are rare, the prominent risk of
255 sensitization and further alloimmunization affects especially patients dependent on
256 recurrent transfusions^{4,5}. Extended blood group typing has proven to be beneficial by
257 reducing the incidence of alloantibody formation^{28,29}. Additionally, studies have shown that
258 the extended genotyping of blood donors markedly increases the number of suitable donors
259 for immunized recipients¹³ and enhances the supply of antigen-negative blood⁶.

260 At present, preventive matching strategies are implemented only for specific patient groups
261 and, despite the obvious advantages of the extended genotyping of donors, the procedure
262 has not been considered feasible covering all blood donors. Over the last decades, the
263 genotyping of different populations has expanded widely. Using machine learning
264 approaches to screen blood donor and research biobank genotyping data may provide a
265 cost-effective solution for enlarging the pool of antigen-negative blood donors. Our random
266 forest classification method infers RBC antigens and HPA-1 from genotype-imputed
267 microarray data. The R package ranger performed fast and handled the dimensionality of
268 input data without problems²¹. The obtained results demonstrated high balanced accuracies
269 both in the Finnish discovery cohort (median 99.8% for the 39 Finnish models) and in the
270 Danish validation cohort (median 99.3% for the 40 Danish models) (**Table 5**). The
271 performance was not affected by nearly a 100-fold size difference between the Finnish and
272 the Danish cohorts (~1,200 vs. ~111,000, respectively).

273 Rh and MNS blood group system antigens have been challenging to determine by
274 sequencing due to complex genetic variation and gene rearrangements^{12,30}. We observed

275 reduced balanced accuracy in the Finnish model for hr^S (93.3%) and the Danish model for C^w
276 (95.3%). However, the other Rh and MNS antigen models, including clinically significant E, e,
277 C, c, S, and s, performed accurately. The balanced accuracies for clinically significant
278 antigens in other systems, including K, Jk^a, Jk^b, Fy^a, and Fy^b, ranged from 95.6% to 100%
279 (**Table 5**).

280 The BOOGIE method for prediction of RBC antigens was published in 2015¹⁴. It builds on 1-
281 NN algorithm and implementation requires genotype sequencing data and curated
282 haplotype tables for the RBC antigen phenotypes. When compared, the Finnish models for
283 ABO and RhD performed better than the BOOGIE method (median balanced accuracy for
284 the Finnish ABO models 100% vs. BOOGIE ABO accuracy 94.2%; balanced accuracy for the
285 Finnish RhD model 98.8% vs. BOOGIE RhD accuracy 94.2%). The observed differences in
286 accuracies could be explained by the potentially limited haplotype tables utilized by
287 BOOGIE. Additionally, the reported results of BOOGIE are based on low number of samples.

288 When applying the Finnish models to the Danish cohort, the observed decrease in balanced
289 accuracies was expected because of the evident genetic, genotyping, and imputation
290 differences between the Finnish and the Danish cohorts (**Table 5**). The Finnish cohort was
291 imputed using population-specific imputation reference panel having no missingness per
292 individual. On the contrary, the Danish cohort was imputed using the North European
293 reference sequence panel resulting in an average missingness of 5%. As random forest is not
294 able to handle missing input data and the important variables of the Finnish models were
295 not fully present in the Danish data, we were obliged to use mean imputation for missing
296 variant dosage data. It is obvious that this approach also introduces errors to the data,
297 which may partly explain the reduced accuracy. The better performance of the Danish
298 models in Danish cohort underlined the benefit of the population-specific training cohort.

299 To our surprise, the Finnish genotyping data had only one variant in the *RHD* region.
300 Nonetheless, the Finnish model for RhD performed with sufficient balanced accuracy in the
301 Finnish cohort (98.8%). Our method combines *RHD* and *RHCE* region variants for the
302 modelling and the high linkage disequilibrium may have supported the classification (**Table**
303 **2**). However, the Finnish model for RhD worked poorly in the Danish cohort (78.4%), which
304 may be attributed to the mean imputation of missing values.

305 The present modelling method is restricted to the RBC antigen typing data available for the
306 training and test data sets, which can be considered as a major limitation because the data
307 for some RBC antigens are scarce. RBC antigens have demonstrated significant diversity
308 among populations and rare blood group variants may not be discovered without
309 substantially large typing numbers. The Danish model for Kn^a failed because of lacking Kn^a-
310 negative samples in the test data set and we were not able to create Finnish models for e.g.,
311 Vel, k, Kp^b, Lu^a, and LW^a.

312 In the future, comprehensive donor and recipient typing and precision matching are likely to
313 increase. A recent publication by van Sambeek *et al.*³¹ demonstrated the feasibility of
314 preventive matching for all genotyped recipients and donors. Our method is suitable for
315 initial screening for antigen-negative donors at biobank-scale, presenting a cost-effective
316 solution for the extended blood group and HPA-1 typing. Additionally, successful prediction
317 of polygenic blood groups may facilitate the research of disease associations in large
318 biobanks.

319 Scripts for random forest modelling and for applying the tested 39 Finnish models are freely
320 available in the GitHub. The implementation is possible in the local computing environment
321 without sensitive data uploads and requires only a moderate level of bioinformatic skills.

322

323 **AUTHOR CONTRIBUTION**

324 K. Hyvärinen, K. Haimila, J. Partanen, and J. Ritari designed the study. The Blood Service
325 Biobank provided the samples and genomic data. K. Haimila supervised blood group typing
326 and provided blood group expertise. K. Hyvärinen and J. Ritari scripted the random forest
327 method, carried the analyses out in the Finnish cohort, and interpret the results. O.B.
328 Pedersen and C. Erikstrup established the Danish cohort. C. Moslemi executed the
329 replications analysis in the Danish cohort. M.L. Olsson, S.R. Ostrowski. and O.B. Pedersen
330 supervised and interpreted the analysis performed in the Danish cohort. K. Hyvärinen
331 drafted the manuscript. All authors contributed to the final version of the manuscript.

332

333 **ACKNOWLEDGEMENTS**

334 We want to thank Dr. Satu Pastila and Ms. Ritva Toivanen at the FRCBS for the collaboration
335 with the blood group typing data. We are also grateful for Ms. Birgitta Rantala, Mr. Petteri
336 Vaskin, Ms. Katariina Karjalainen, Ms. Nina Nikiforow, Ms. Jonna Clancy, and Dr. Mikko
337 Arvas and Dr. Tiina Wahlfors at the Blood Service Biobank for their help in handling the data
338 and samples, and Dr. Jaana Mättö and the personnel at the FRCBS Blood Group Unit for
339 blood group typing analyses.

340 From Denmark, we wish to thank the Danish blood donors and deCODE Genetics for
341 genotyping the Danish cohort.

342

343 **DISCLOSURE AND FUNDING**

344 M.L. Olsson is an inventor on patents about Vel blood group genotyping (unrelated to the
345 methods and models presented in this study) and owns 50% each of the shares in BLUsang
346 AB, an incorporated consulting firm, which receives royalties for said patents. The other
347 authors declare no conflicts of interest.

348 The study was partially supported by funding from the Government of Finland VTR funding,
349 the Academy of Finland, the Finnish Cancer Association, and Business Finland. The study of
350 the Danish cohort was supported by Independent Research Fund Denmark (project number
351 0214-00127B), Bloddonornes forskningsfond, and A.P Møller Fonden. M.L. Olsson is a
352 Wallenberg Clinical Scholar funded by Knut and Alice Wallenberg Foundation.

353

354 **SUPPORTING INFORMATION STATEMENT**

355 Supplementary Information is online.

REFERENCES

1. Goel R, Tobian AAR, Shaz BH. Noninfectious transfusion-associated adverse events and their mitigation strategies. *Blood*. 2019;133(17):1831-1839. doi:10.1182/blood-2018-10-833988
2. Hendrickson JE, Delaney M. Hemolytic Disease of the Fetus and Newborn: Modern Practice and Future Investigations. *Transfus Med Rev*. 2016;30(4):159-164. doi:10.1016/j.tmr.2016.05.008
3. Bussel JB, Vander Haar EL, Berkowitz RL. New developments in fetal and neonatal alloimmune thrombocytopenia. *Am J Obstet Gynecol*. 2021;225(2):120-127. doi:10.1016/j.ajog.2021.04.211
4. Hendrickson JE, Tormey CA, Shaz BH. Red blood cell alloimmunization mitigation strategies. *Transfus Med Rev*. 2014;28(3):137-144. doi:10.1016/j.tmr.2014.04.008
5. Evers D, Middelburg RA, de Haas M, et al. Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study. *Lancet Haematol*. 2016;3(6):e284-e292. doi:10.1016/S2352-3026(16)30019-9
6. Flegel WA, Gottschall JL, Denomme GA. Implementing mass-scale red cell genotyping at a blood center. *Transfusion*. 2015;55(11):2610-2615. doi:10.1111/trf.13168
7. Cone Sullivan JK, Gleadall N, Lane WJ. Blood Group Genotyping. *Clin Lab Med*. 2022;42(4):645-668. doi:10.1016/J.CLL.2022.09.016
8. Lane WJ, Westhoff CM, Gleadall NS, et al. Automated typing of red blood cell and platelet antigens: a whole-genome sequencing study. *Lancet Haematol*. 2018;5(6):e241-e251. doi:10.1016/S2352-3026(18)30053-X
9. Veldhuisen B, Van Der Schoot CE, De Haas M. Blood group genotyping: From patient to high-throughput donor screening. *Vox Sang*. 2009;97(3):198-206. doi:10.1111/j.1423-0410.2009.01209.x
10. Hyun J, Oh S, Hong YJ, Park KU. Prediction of various blood group systems using Korean whole-genome sequencing data. *PLoS One*. 2022;17(6). doi:10.1371/JOURNAL.PONE.0269481

11. Möller M, Jöud M, Storry JR, Olsson ML. ErythroGene: a database for in-depth analysis of the extensive variation in 36 blood group systems in the 1000 Genomes Project. *Blood Adv.* 2016;1(3):240-249. doi:10.1182/bloodadvances.2016001867
12. ISBT Blood Group Allele Tables. [https://www.isbtweb.org/isbt-working-parties/rcibgt/blood-group-allele-tables.html#blood group allele tables](https://www.isbtweb.org/isbt-working-parties/rcibgt/blood-group-allele-tables.html#blood%20group%20allele%20tables)
13. Gleadall NS, Veldhuisen B, Gollub J, et al. Development and validation of a universal blood donor genotyping platform: A multinational prospective study. *Blood Adv.* 2020;4(15):3495-3506. doi:10.1182/bloodadvances.2020001894
14. Giollo M, Minervini G, Scalzotto M, Leonardi E, Ferrari C, Tosatto SCE. BOOGIE: Predicting blood groups from high throughput sequencing data. *PLoS One.* 2015;10(4):1-15. doi:10.1371/journal.pone.0124579
15. Breiman L. Bagging predictors. *Mach Learn.* 1996;26(2):123-140.
16. Breiman L. Random forests. *Mach Learn.* 2001;45(1):5-32. doi:10.1023/A:1010933404324/METRICS
17. Zheng X, Shen J, Cox C, et al. HIBAG—HLA genotype imputation with attribute bagging. *Pharmacogenomics J.* 2014;14(2):192-200. doi:10.1038/tpj.2013.18
18. Ritari J, Hyvärinen K, Clancy J, FinnGen, Partanen J, Koskela S. Increasing accuracy of HLA imputation by a population-specific reference panel in a FinnGen biobank cohort. *NAR Genomics Bioinforma.* 2020;2(2):lqaa030. doi:10.1093/nargab/lqaa030
19. Vukcevic D, Traherne JA, Næss S, et al. Imputation of KIR Types from SNP Variation Data. *Am J Hum Genet.* 2015;97(4):593-607. doi:10.1016/j.ajhg.2015.09.005
20. Ritari J, Hyvärinen K, Partanen J, Koskela S. KIR gene content imputation from single-nucleotide polymorphisms in the Finnish population. *PeerJ.* 2022;10(e12692). doi:10.7717/peerj.12692
21. Wright MN, Ziegler A. ranger: A Fast Implementation of Random Forests for High Dimensional Data in C++ and R. *J Stat Softw.* 2017;77(1):1–17. doi:10.18637/jss.v077.i01

22. Pedersen OB, Erikstrup C, Kotzé SR, et al. The Danish Blood Donor Study: A large, prospective cohort and biobank for medical research. *Vox Sang*. 2012;102(3):271. doi:10.1111/j.1423-0410.2011.01553.x
23. Hansen TF, Banasik K, Erikstrup C, et al. DBDS Genomic Cohort, a prospective and comprehensive resource for integrative and temporal analysis of genetic, environmental and lifestyle factors affecting health of blood donors. *BMJ Open*. 2019;9(6). doi:10.1136/bmjopen-2018-028401
24. R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing; 2023. <https://www.r-project.org/>
25. Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. *J Open Source Softw*. 2019;4(43):1686. doi:10.21105/joss.01686
26. Kuhn M. Building Predictive Models in R Using the caret Package. *J Stat Softw*. 2008;28(5):1–26. doi:10.18637/jss.v028.i05
27. Monaghan TF, Rahman SN, Agudelo CW, et al. Foundational Statistical Principles in Medical Research: Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value. *Medicina (Kaunas)*. 2021;57(5). doi:10.3390/medicina57050503
28. Lasalle-Williams M, Nuss R, Le T, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). *Transfusion*. 2011;51(8):1732-1739. doi:10.1111/J.1537-2995.2010.03045.X
29. Schonewille H, Honohan Á, Van Der Watering LMG, et al. Incidence of alloantibody formation after ABO-D or extended matched red blood cell transfusions: a randomized trial (MATCH study). *Transfusion*. 2016;56(2):311-320. doi:10.1111/TRF.13347
30. Zhang Z, An HH, Vege S, et al. Accurate long-read sequencing allows assembly of the duplicated RHD and RHCE genes harboring variants relevant to blood transfusion. *Am J Hum Genet*. 2022;109(1):180-191. doi:10.1016/j.ajhg.2021.12.003
31. van Sambeek JHJ, van der Schoot CE, van Dijk NM, Schonewille H, Janssen MP.

Extended red blood cell matching for all transfusion recipients is feasible. *Transfus Med.* 2022;32(3):221-228. doi:10.1111/TME.12831

FIGURE LEGENDS

Figure 1. Study design. Random forest classification models were generated using Finnish reference data set (n = 1,192). Allele dosages of genes determining RBC antigens/phenotypes and HPA-1 were combined with the antigen typing data. The dataset was divided randomly to train and test data sets. Random forest modelling was executed in the training data set (n = 596) and the important variables were selected using permutation. The models were evaluated in the test data set (n = 596) for prediction accuracy and errors. The final models were fitted using the full data set and both models and the method were validated in the Danish cohort (n = 111,677).

Figure 2. Confusion matrices of the Finnish models in the Finnish test data set. Confusion matrices for the Finnish antigen classification models in the Finnish test data set are presented in alphabetical order of the blood group systems. The RBC antigen/phenotype and HPA-1 typing results are on the x-axis and the model predictions on the y-axis. The antigen-negative samples are denoted by 0 and the antigen-positive samples by 1 on both axes. The numbers of true positive and true negative samples are depicted in the green boxes and the numbers of false positive and false negative samples in the red boxes.

Figure 3. Posterior probability boxplots of the Finnish models in the Finnish test data set. Posterior probability boxplots for the Finnish antigen classification models in the Finnish test data set are presented in alphabetical order of the blood group systems. The RBC antigen/phenotype and HPA-1 typing results are on the x-axis and the antigen-negative samples are denoted by 0 and the antigen-positive samples by 1. The posterior probabilities for samples range from 0 to 1 and are presented on the y-axis. Samples are depicted as open circles.

Table 1. Blood group/HPA-1 antigen typing information of the Finnish and Danish cohorts.

Blood group/HPA system	Antigen ^a	Finnish cohort(n)	Antigen positivity in the Finnish cohort(%)	Danish cohort(n)	Antigen positivity in the Danish cohort(%)
ABO	A	1,192	40.9	111,656	41.2
ABO	A ₁	70	62.9	17,541	75.3
ABO	A ₂	70	38.6	433	27.0
ABO	AB	1,192	8.0	111,656	4.4
ABO	B	1,192	8.2	111,656	10.2
ABO	O	1,192	42.9	111,656	44.2
Cartwright	Yt ^a	NA	NA	7,640	99.6
Cartwright	Yt ^b	1,160	6.2	7,362	7.3
Colton	Co ^a	1,162	99.8	7,490	98.5
Colton	Co ^b	1,164	7.3	8,277	9.2
Dombrock	Do ^a	1,162	53.1	7,352	62.9
Dombrock	Do ^b	1,162	90.7	7,352	84.6
Duffy	Fy ^a	1,177	67.0	77,920	67.0
Duffy	Fy ^b	1,175	75.1	71,096	80.8
Gerbich	Ls ^a	190	3.2	NA	NA
HPA-1	HPA-1a	232	91.4	518	97.1
HPA-1	HPA-1b	62	43.5	518	30.7
Kell	K	1,192	4.7	96,497	7.8
Kell	k	NA	NA	14,332	99.0
Kell	Kp ^a	1,177	2.6	22,497	2.4
Kell	Kp ^b	NA	NA	10,350	99.9
Kell	UJ ^a	219	15.5	NA	NA
Kidd	Jk ^a	1,177	72.6	77,986	76.6
Kidd	Jk ^b	1,177	68.5	71,840	72.7
Knops	Kn ^a	NA	NA	3,462	99.9
Knops	Kn ^b	NA	NA	3,462	6.8
Landsteiner-Wiener	LW ^b	327	5.2	NA	NA
Lewis	Le ^a	253	10.2	9,220	17.4
Lewis	Le ^b	253	80.2	8,925	56.5
Lutheran	Lu ^a	1,164	3.6	9,615	8.6
MNS	M	1,177	87.7	29,642	78.1
MNS	N	1,177	59.0	14,837	71.6
MNS	S	1,177	54.2	28,949	50.4
MNS	s	1,177	87.6	24,291	90.9
P1PK	P1	253	75.9	7,465	77.4
Rh	C	1,192	54.4	44,451	63.3
Rh	c	1,192	79.4	42,968	82.2
Rh	C ^w	1,177	3.2	40,720	3.3
Rh	C ^x	337	12.2	NA	NA
Rh	D	1,192	71.6	111,667	79.5
Rh	E	1,192	19.9	89,289	28.1
Rh	e	1,192	96.2	82,467	97.3

Rh	hr ^B	1,162	96.4	NA	NA
Rh	hr ^S	1,162	97.3	NA	NA
Vel	Vel	NA	NA	11,755	99.9

NA, data not available.

^a O, A₁, and A₂ and in this column refer to phenotype.

Table 2. Characteristics of the Finnish classification models.

Blood group/HPA system	Antigen ^a	Genes analyzed	n(variants available)	n(model variants)	Prediction error ^b
ABO	ABO	<i>ABO</i>	496	164	8.68E-04
ABO	A ₁	<i>ABO</i>	496	18	1.29E-03
ABO	A ₂	<i>ABO</i>	496	43	2.20E-02
Cartwright	Yt ^b	<i>ACHE</i>	62	12	0.00E+00
Colton	Co ^a	<i>AQP1</i>	108	15	4.26E-04
Colton	Co ^b	<i>AQP1</i>	108	39	2.03E-03
Dombrock	Do ^a	<i>ART4</i>	109	17	6.97E-05
Dombrock	Do ^b	<i>ART4</i>	109	17	0.00E+00
Duffy	Fy ^a	<i>ACKR1</i>	57	25	6.80E-05
Duffy	Fy ^b	<i>ACKR1</i>	57	26	4.32E-03
Gerbich	Le ^a	<i>GYPC</i>	342	81	7.71E-03
HPA-1	HPA-1a	<i>ITGB3</i>	386	24	1.74E-03
HPA-1	HPA-1b	<i>ITGB3</i>	386	73	2.06E-02
Kell	K	<i>KEL</i>	127	33	2.93E-05
Kell	Kp ^a	<i>KEL</i>	127	26	8.56E-05
Kell	UI ^a	<i>KEL</i>	127	21	2.01E-04
Kidd	Jk ^a	<i>SLC14A1</i>	622	18	1.62E-04
Kidd	Jk ^b	<i>SLC14A1</i>	622	178	8.14E-04
Landsteiner-Wiener	Lw ^b	<i>ICAM4</i>	35	19	4.27E-03
Lewis	Le ^a	<i>FUT2, FUT3</i>	199	45	4.13E-03
Lewis	Le ^b	<i>FUT2, FUT3</i>	199	88	1.56E-02
Lutheran	Lu ^a	<i>BCAM</i>	124	14	9.47E-04
MNS	M	<i>GYPA, GYPB, GYPC</i>	688	132	6.80E-03
MNS	N	<i>GYPA, GYPB, GYPC</i>	688	214	1.18E-02
MNS	S	<i>GYPA, GYPB, GYPC</i>	688	44	1.54E-05
MNS	s	<i>GYPA, GYPB, GYPC</i>	688	49	1.19E-04
P1PK	P1	<i>A4GALT, B3GALNT1</i>	368	135	1.73E-02
Rh	C	<i>RHCE, RHD</i>	266	108	9.23E-03
Rh	c	<i>RHCE, RHD</i>	266	68	3.23E-03
Rh	C ^w	<i>RHCE, RHD</i>	266	53	2.80E-03
Rh	C ^x	<i>RHCE, RHD</i>	266	12	4.70E-03
Rh	D	<i>RHCE, RHD</i>	266	113	7.47E-03
Rh	E	<i>RHCE, RHD</i>	266	80	1.07E-03
Rh	e	<i>RHCE, RHD</i>	266	23	1.33E-03
Rh	hr ^B	<i>RHCE, RHD</i>	266	20	1.39E-03
Rh	hr ^S	<i>RHCE, RHD</i>	266	22	7.71E-03

^a O, A₁, and A₂ and in this column refer to phenotype.

^b Misclassification frequency obtained from out-of-bag data.

Table 3. Accuracy metrics for the Finnish models in the Finnish test data set.

Blood group/HPA system	Antigen ^a	Sensitivity	Specificity	Positive predictive value	Negative predictive value	Balanced accuracy
ABO	A	0.997	1.000	1.000	0.996	0.999
ABO	A ₁	1.000	1.000	1.000	1.000	1.000
ABO	A ₂	1.000	1.000	1.000	1.000	1.000
ABO	AB	1.000	1.000	1.000	1.000	1.000
ABO	B	1.000	1.000	1.000	1.000	1.000
ABO	O	1.000	0.996	0.997	1.000	0.998
Cartwright	Yt ^b	1.000	1.000	1.000	1.000	1.000
Colton	Co ^a	1.000	1.000	1.000	1.000	1.000
Colton	Co ^b	1.000	0.952	0.996	1.000	0.976
Dombrock	Do ^a	1.000	1.000	1.000	1.000	1.000
Dombrock	Dob	1.000	1.000	1.000	1.000	1.000
Duffy	Fy ^a	1.000	1.000	1.000	1.000	1.000
Duffy	Fy ^b	0.979	1.000	1.000	0.993	0.990
Gerbich	Ls ^a	1.000	0.667	0.989	1.000	0.833
HPA-1	HPA-1a	0.900	1.000	1.000	0.991	0.950
HPA-1	HPA-1b	1.000	1.000	1.000	1.000	1.000
Kell	K	1.000	1.000	1.000	1.000	1.000
Kell	Kp ^a	1.000	1.000	1.000	1.000	1.000
Kell	UJ ^a	1.000	1.000	1.000	1.000	1.000
Kidd	Jk ^a	1.000	1.000	1.000	1.000	1.000
Kidd	Jk ^b	0.995	1.000	1.000	0.998	0.997
Landsteiner-Wiener	LW ^b	0.994	1.000	1.000	0.889	0.997
Lewis	Le ^a	0.991	1.000	1.000	0.929	0.996
Lewis	Le ^b	0.880	1.000	1.000	0.971	0.940
Lutheran	Lu ^a	1.000	1.000	1.000	1.000	1.000
MNS	M	0.972	0.994	0.959	0.996	0.983
MNS	N	0.992	0.986	0.980	0.994	0.989
MNS	S	1.000	1.000	1.000	1.000	1.000
MNS	s	1.000	1.000	1.000	1.000	1.000
P1PK	P1	1.000	0.979	0.938	1.000	0.990
Rh	C	0.978	1.000	1.000	0.982	0.989
Rh	c	1.000	0.994	0.976	1.000	0.997
Rh	C ^w	0.996	1.000	1.000	0.905	0.998
Rh	C ^x	0.986	1.000	1.000	0.909	0.993
Rh	D	0.970	0.993	0.982	0.988	0.982
Rh	E	1.000	0.975	0.994	1.000	0.987
Rh	e	1.000	0.998	0.957	1.000	0.999
Rh	hr ^B	1.000	0.998	0.955	1.000	0.999
Rh	hr ^S	0.933	0.986	0.636	0.998	0.960

^a O, A₁, and A₂ and in this column refer to phenotype.

Table 4. Accuracy metrics for the Danish models in the Danish test data set.

Blood group/HPA system	Antigen ^a	Sensitivity	Specificity	Positive predictive value	Negative predictive value	Balanced accuracy
ABO	A	0.999	0.998	0.998	0.999	0.998
ABO	A ₁	0.971	0.992	0.974	0.991	0.981
ABO	A ₂	0.975	0.810	0.933	0.922	0.893
ABO	AB	1.000	0.996	1.000	0.997	0.998
ABO	B	1.000	0.998	1.000	0.998	0.999
ABO	O	0.999	0.997	0.998	0.999	0.998
Cartwright	Yt ^a	1.000	1.000	0.933	1.000	1.000
Cartwright	Yt ^b	0.999	1.000	1.000	0.985	0.999
Colton	Co ^a	0.500	1.000	0.750	0.999	0.750
Colton	Co ^b	0.993	0.950	0.995	0.928	0.971
Dombrock	Do ^a	1.000	0.999	0.999	1.000	1.000
Dombrock	Do ^b	0.996	1.000	0.998	0.999	0.998
Duffy	Fy ^a	0.995	0.998	0.996	0.998	0.997
Duffy	Fy ^b	0.963	0.999	0.995	0.991	0.981
HPA-1	HPA-1a	1.000	1.000	1.000	1.000	1.000
HPA-1	HPA-1b	0.994	1.000	1.000	0.988	0.997
Kell	K	0.996	0.906	0.992	0.956	0.951
Kell	k	0.681	1.000	0.942	0.997	0.840
Kell	Kp ^a	0.999	0.888	0.997	0.956	0.944
Kell	Kp ^b	0.400	1.000	1.000	0.999	0.700
Kidd	Jk ^a	0.996	0.998	0.995	0.999	0.997
Kidd	Jk ^b	0.996	0.999	0.997	0.998	0.997
Knops	Kn ^a	0.000	1.000	NA	0.999	0.500
Knops	Kn ^b	1.000	1.000	1.000	1.000	1.000
Lewis	Le ^a	0.996	0.986	0.997	0.981	0.991
Lewis	Le ^b	0.499	0.979	0.948	0.717	0.739
Lutheran	Lu ^a	0.997	0.931	0.994	0.971	0.964
Lutheran	Lu ^b	0.750	1.000	0.923	0.999	0.875
MNS	M	0.989	0.998	0.993	0.997	0.994
MNS	N	0.981	0.990	0.975	0.993	0.986
MNS	S	0.997	0.997	0.997	0.997	0.997
MNS	s	0.985	0.999	0.995	0.998	0.992
P1PK	P1	0.939	0.996	0.986	0.982	0.968
Rh	C	0.994	0.999	0.999	0.997	0.997
Rh	c	0.997	0.999	0.995	0.999	0.998
Rh	C ^w	0.998	0.898	0.997	0.952	0.948
Rh	D	0.994	0.999	0.997	0.998	0.997
Rh	E	0.999	0.989	0.996	0.998	0.994
Rh	e	0.962	1.000	0.993	0.999	0.981
Vel	Vel	0.568	1.000	0.955	0.999	0.784

^a O, A₁, and A₂ and in this column refer to phenotype.

Table 5. Balanced accuracies for the Finnish and Danish models in full data sets.

Blood group/HPA system	Antigen ^a	Balanced accuracy		
		Finnish full data set Finnish models	Danish full data set Finnish models	Danish full data set Danish models
ABO	A	0.999	0.995	0.999
ABO	A ₁	1.000	0.980	0.984
ABO	A ₂	0.981	0.894	0.891
ABO	AB	1.000	0.998	0.999
ABO	B	1.000	0.987	0.999
ABO	O	0.999	0.995	0.998
Cartwright	Yt ^a	NA	NA	1.000
Cartwright	Yt ^b	1.000	0.998	0.998
Colton	Co ^a	1.000	0.833	0.833
Colton	Co ^b	0.988	0.926	0.963
Dombrock	Do ^a	1.000	0.999	0.999
Dombrock	Do ^b	1.000	0.999	0.999
Duffy	Fy ^a	1.000	0.979	0.997
Duffy	Fy ^b	0.993	0.971	0.980
Gerbich	Ls ^a	0.917	NA	NA
HPA-1	HPA-1a	1.000	1.000	1.000
HPA-1	HPA-1b	0.986	0.939	0.999
Kell	K	1.000	0.916	0.956
Kell	k	NA	NA	0.838
Kell	Kp ^a	1.000	0.935	0.961
Kell	Kp ^b	NA	NA	0.750
Kell	UJ ^a	1.000	NA	NA
Kidd	Jk ^a	1.000	0.995	0.997
Kidd	Jk ^b	0.999	0.662	0.997
Knops	Kn ^a	NA	NA	0.750
Knops	Kn ^b	NA	NA	1.000
Landsteiner_Wiener	LW ^b	0.998	0.500	NA
Lewis	Le ^a	0.998	0.981	0.989
Lewis	Le ^b	0.968	0.729	0.736
Lutheran	Lu ^a	0.988	0.956	0.964
Lutheran	Lu ^b	NA	NA	0.828
MNS	M	0.984	0.970	0.993
MNS	N	0.988	0.947	0.987
MNS	S	1.000	0.995	0.997
MNS	s	1.000	0.988	0.993
P1PK	P1	0.984	0.500	0.965
Rh	C	0.989	0.646	0.997
Rh	c	0.997	0.500	0.997
Rh	C ^w	0.999	0.918	0.953
Rh	C ^x	0.997	NA	NA
Rh	D	0.988	0.784	0.997
Rh	E	0.998	0.992	0.995
Rh	e	0.988	0.982	0.984
Rh	hr ^B	0.988	NA	NA
Rh	hr ^S	0.933	NA	NA
Vel	Vel	NA	NA	0.811

NA, data not available.

^a O, A₁, and A₂ and in this column refer to phenotype.




Figure 1. Study design.




Figure 2. Confusion matrices of the Finnish models in the Finnish test data set.




Figure 3. Posterior probability boxplots of the Finnish models in the Finnish test data set.